Tech Company Financing Transactions
Elion Therapeutics Funding Round
On 6/17/2024, Elion Therapeutics raised $81 million in Series B funding from AMR Action Fund, Deerfield Management Company and IllinoisVENTURES.
Transaction Overview
Company Name
Announced On
6/17/2024
Transaction Type
Venture Equity
Amount
$81,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of SF001, a polyene antifungal designed for reduced toxicity.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
New York, NY Undisclosed
USA
New York, NY Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Elion Therapeutics is a biotechnology company focused on combating life-threatening invasive fungal infections. Our goal is to provide patients and clinicians with new therapies that address critical unmet needs in antifungal efficacy and safety.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Kieren Marr
VP - Regulatory Affairs
Carmen Betancourt-Riche
Browse more venture capital transactions:
Prev: 6/17/2024: Complete Solaria venture capital transaction
Next: 6/17/2024: Hona venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs